|  |  |  |  |
| --- | --- | --- | --- |
| Timepoint post HSCT (auto and allo) | Pathogens Protected Against | Vaccine | Trade Name (Equivalent alternative may be used) |
| SARS-CoV-2 re-vaccination Age 5-11 | | | |
| 3-6 months | SARS-CoV-2 | Pfizer-BioNTech mRNA BNT162b2 (Dose 1) [[1]](#endnote-1) | As per vaccine name |
| Minimum 12 weeks post-dose 1 | SARS-CoV-2 | Pfizer-BioNTech mRNA BNT162b2 (Dose 2) 1 | As per vaccine name |
| SARS-CoV-2 re-vaccination Age 12-17 | | | |
| 3-6 months | SARS-CoV-2 | Pfizer-BioNTech mRNA BNT162b2 (Dose 1)  *OR*  Moderna mRNA 1273 (Dose 1  *OR*  Novavax NVX-CoV2373 (Dose 1)2 | As per vaccine name |
| Minimum 8 weeks post-dose 1 | SARS-CoV-2 | Pfizer-BioNTech mRNA BNT162b2 (Dose 2)  *OR*  Moderna mRNA 1273 (Dose 2)  *OR*  Novavax NVX-CoV2373 (Dose 1)2 | As per vaccine name |
| 8 weeks post dose 2 | SARS-CoV-2 | Pfizer-BioNTech mRNA BNT162b2 (Dose 3)  *OR*  Moderna mRNA 1273 (Dose 3)  *OR*  Novavax NVX-CoV2373 (Dose 1)2 | As per vaccine name |
| Routine re-vaccination Age <18 | | | |
| Annually from 6 months (Consider from 3 months) | Seasonal Influenza | Seasonal inactivated Influenza vaccine | As per vaccine name |
| 6 months | Diphtheria, tetanus, pertussis, polio, *Haemophilus influenzae* b, Hepatitis B  Meningococcal B  *Streptococcus* *pneumoniae*  Human Papillomavirus3 | DTaP/IPV/Hib/HepB (dose 1)  Men B (dose 1)  PCV13 (dose 1)  Quadrivalent HPV (dose 1) | Infanrix hexa or Vaxelis  Bexsero  Prevenar 13  Gardasil |
| 7 months | Diphtheria, tetanus, pertussis, polio, *Haemophilus influenzae* b, Hepatitis B  *Streptococcus* *pneumoniae*  Human Papillomavirus3 | DTaP/IPV/Hib/HepB (dose 2)  PCV13 (dose 2)  Quadrivalent HPV (dose 2) | Infanrix hexa or Vaxelis  Prevenar 13  Gardasil |
| 8 months | Diphtheria, tetanus, pertussis, polio, *Haemophilus influenzae* b, Hepatitis B  Meningococcal B  Meningococcal ACWY  *Streptococcus* *pneumoniae* | DTaP/IPV/Hib/HepB (dose 3)  MenB (dose 2)  Men ACWY (dose 1)  PCV13 (dose 3) | Infanrix hexa or Vaxelis  Bexsero  Nimenrix or Menveo  Prevenar 13 |
| 12 months | Human Papillomavirus3 | Quadrivalent HPV (dose 3) | Gardasil |
| 18 months | Meningococcal ACWY  Meningococcal B  *Streptococcus* *pneumonia*e | Men ACWY (dose 2)  Men B (Booster)  PPSV23 Or PCV134 (Booster) | Nimenrix or Menveo  Bexsero  Pneumovax  Prevenar 13 |
| 24 months | Measles, Mumps, Rubella5  Varicella  Human Papillomavirus3 | MMR (dose 1) *live vaccine*  Varicella vaccine (dose 1) *live vaccine*  Quadrivalent HPV (dose 3) | MMR VaxPro or Priorix  Varivax or Varilrix  Gardasil |
| 26 months | Varicella | Varicella vaccine (dose 2) *live vaccine* | Varivax or Varilrix |
| 30 months | Measles, Mumps, Rubella5 | MMR (dose 2) *live vaccine* | MMR VaxPro or Priorix |
| 3 years | Diphtheria, tetanus, pertussis and polio | DTaP/IPV (Booster 1) | Repevax or Boostrix IPV |
| 14 years | Diphtheria tetanus, polio | Td/IPV (Booster 2) | Revaxis |

1. The paediatric formulation (10 micrograms) of the Pfizer-BioNTech mRNA vaccine should be administered to patients aged 5-11

   2Novavax NVX-CoV2373 to be used only if mRNA vaccine use in clinically contraindicated

   3HPV vaccine should be offered to all children aged 12 or over

   4PPSV23 if no GvHD or Immunosuppresive therapy (IST), PCV13 if GvHD or IST

   5Criteria for administration of live vaccines.  i) 24 months post HSCT ii) No GvHD iii) No IST for 12 months  iv) In remission v) No IVIg in last 3 months. Nb measles serology not mandated in paediatric population [↑](#endnote-ref-1)